Dupilumab

證據等級: L5

預測適應症: 10 個

Dupilumab: From Atopic Dermatitis / Type 2 Inflammation to Bronchitis

⚠️ Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application.

One-Sentence Summary

Dupilumab (Dupixent®) is a fully human monoclonal antibody that blocks the IL-4 receptor alpha subunit (IL-4Rα), with established efficacy in Type 2 inflammatory diseases including atopic dermatitis, moderate-to-severe asthma, and chronic rhinosinusitis with nasal polyps. The TxGNN model predicts it may be effective for Bronchitis, with 1 clinical trial and 6 publications currently supporting this direction. Evidence is primarily mechanistic extrapolation from closely related airway conditions, as no bronchitis-specific Phase 2/3 RCT has been completed to date.

Quick Overview

Item	Content
Original Indication	No indication registered in the Danish Medicines Agency (Laegemiddelstyrelsen) dataset; globally established for atopic dermatitis and asthma (EMA-authorised)
Predicted New Indication	Bronchitis
TxGNN Prediction Score	99.92%
Evidence Level	L3
Denmark Market Status	Not marketed (no local authorisations on record)
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Dupilumab is a fully human IgG4 monoclonal antibody that binds the shared alpha subunit of the IL-4 and IL-13 receptors (IL-4Rα), simultaneously blocking downstream JAK-STAT signalling of both cytokines. IL-4 and IL-13 are the principal drivers of Type 2 (Th2) inflammation: they promote IgE class-switching, goblet cell hyperplasia, mucus hypersecretion, and subepithelial fibrosis. This mechanism has been clinically validated in atopic dermatitis, moderate-to-severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), prurigo nodularis, and eosinophilic oesophagitis.

Chronic bronchitis — particularly phenotypes with eosinophilic airway inflammation or confirmed Type 2 immune activation — shares precisely this pathophysiological axis. IL-13, in particular, drives mucin overproduction and goblet cell metaplasia in the bronchial mucosa, while IL-4 amplifies Th2 polarisation and eosinophil recruitment. The “united airway” hypothesis positions upper airway sinusitis, nasal polyposis, asthma, and lower airway bronchitis along the same biological continuum, making IL-4Rα blockade mechanistically plausible across all sites. This continuum is supported by the inclusion of CRSsNP (NCT04362501) in the current evidence pack, where Th2 airway inflammation responds to dupilumab despite differing anatomical targets.

However, it is essential to note that mechanistic plausibility does not equate to confirmed clinical benefit. The critical gap is the absence of a Phase 2 or Phase 3 RCT directly enrolling bronchitis patients. Smoker-predominant neutrophilic bronchitis — the most common phenotype — is unlikely to respond to Th2 blockade and was actively excluded from most asthma and CRSsNP dupilumab trials. Patient phenotyping using blood eosinophil count and fractional exhaled nitric oxide (FeNO) will be essential to identify a biologically responsive subpopulation.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04362501	Phase 2	Completed	33	Dupilumab in chronic rhinosinusitis without nasal polyps (CRSsNP). Evaluates clinical effectiveness across Type 2 and non-Type 2 disease endotypes. CRSsNP shares IL-4/IL-13-driven inflammation with bronchitis but involves the upper airway; results provide indirect mechanistic support but cannot be directly extrapolated to bronchitis outcomes.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
30273510	2019	Systematic Review / Meta-Analysis	J Asthma	Pooled analysis of RCTs confirms dupilumab efficacy and safety in uncontrolled asthma; reduced exacerbation rates and improved FEV1. Provides the strongest mechanistic bridge to Type 2 bronchitis.
34597534	2022	RCT Extension	Lancet Respir Med	TRAVERSE study: long-term (>1 year) dupilumab safety and efficacy in moderate-to-severe asthma. Demonstrates sustained reduction in exacerbations and acceptable long-term safety profile.
38488768	2024	Review	Pediatr Pulmonol	Discusses novel therapies for eosinophilic paediatric plastic bronchitis; identifies IL-4/IL-13 blockade as a mechanistically relevant approach, offering the most direct literature link to bronchitis specifically.
32428511	2020	Mechanistic / Imaging Study	Chest	Anti-T2 biologic treatment (dupilumab) improves ventilation defect patterns visualised by inhaled gas MRI in eosinophilic asthma. Demonstrates objective functional improvement in small airway obstruction driven by eosinophilic inflammation.
39904363	2025	Comprehensive Review	Tuberc Respir Dis	Reviews pharmacologic strategies for preventing COPD exacerbations, including novel biologic agents targeting Type 2 pathways; contextualises dupilumab within the broader chronic airway disease treatment landscape.
30196731	2018	Review	Expert Opin Pharmacother	Addresses challenges in treating asthma overlapping with smoking-induced chronic bronchitis and emphysema (asthma-COPD overlap). Highlights that smokers are routinely excluded from biologic trials — a key gap affecting evidence translation to typical bronchitis populations.

Denmark Market Information

Dupilumab has no marketing authorisation recorded in the Danish Medicines Agency (Laegemiddelstyrelsen) registry in this dataset.

Important context for clinicians: Dupilumab (Dupixent®) holds a centralised EU marketing authorisation issued by the European Medicines Agency (EMA), valid in all EU/EEA member states including Denmark. Approved indications include moderate-to-severe atopic dermatitis (adults, adolescents, and children ≥6 months), moderate-to-severe asthma with Type 2 inflammation, chronic rhinosinusitis with nasal polyps, prurigo nodularis, and eosinophilic oesophagitis. Healthcare professionals should consult the current EMA SmPC for Dupixent® for up-to-date prescribing information and reimbursement status with Sundhedsstyrelsen/Medicinrådet.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

Specific safety data (key warnings, contraindications, and drug-drug interaction data) were not retrievable from this evidence pack. Based on the drug class (IL-4Rα monoclonal antibody), clinicians should be aware of class-associated considerations including conjunctivitis, injection site reactions, and potential for paradoxical inflammatory responses (e.g., psoriasiform eruptions). Formal SmPC review is required prior to any clinical application.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic rationale for dupilumab in Type 2-phenotype bronchitis is biologically sound and supported by robust data from directly adjacent indications (asthma, CRSsNP). However, no bronchitis-specific Phase 2 or Phase 3 RCT has been completed, and current evidence is rated L3 (mechanistic extrapolation and observational studies only). Clinical translation in a general bronchitis population cannot be recommended without dedicated prospective evidence, particularly given the heterogeneity of bronchitis phenotypes and the limited likelihood of benefit in the neutrophilic/smoking-related majority.

To proceed, the following is needed:

Phase 2 RCT targeting bronchitis patients enriched for Type 2 biomarkers (blood eosinophils ≥300 cells/μL or FeNO ≥25 ppb) using validated endpoints (e.g., exacerbation rate, symptom score, sputum eosinophil count)
Phenotype stratification strategy: clearly distinguish eosinophilic bronchitis from neutrophilic/smoking-related bronchitis before enrolment — the current evidence supports only the former
SmPC and pharmacovigilance review for dupilumab in the target bronchitis population, including assessment of any contraindications relevant to comorbid COPD or smoker populations
Regulatory and reimbursement pathway assessment in Denmark via Medicinrådet/Sundhedsstyrelsen, given the off-label nature of this proposed indication
Data gap remediation: obtain the full Dupixent® Danish prescribing information from the EMA/Laegemiddelstyrelsen to enable a complete safety assessment before advancing to clinical studies
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.